ERIS · Healthcare
Finance cost rose fast and now takes a large bite of operating profit. New borrowing, or a higher rate?
Finance cost ₹59.0 cr, +268.8% on the year; 22% of EBITDA.
Source: Quarterly statements
Core profit grew faster than reported profit: one-offs held the headline down.
Reported profit −21.3% on the year; profit before other income, exceptional items and tax +0.8%.
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹505 cr | ₹486 cr | ₹551 cr | ₹720 cr | ₹741 cr | ₹727 cr | ₹705 cr | ₹773 cr | ₹792 cr | ₹807 cr | ₹757 cr | ₹873 cr |
| YoY | — | — | — | +54% | +47% | +50% | +28% | +7% | +7% | +11% | +7% | +13% |
| EBITDA margin | 35.8% | 36.2% | 26.9% | 34.7% | 35.8% | 34.4% | 35.7% | 35.8% | 36.4% | 34.9% | 35.9% | 33.9% |
| Other income, % of PBT | 2% | 3% | 19% | 2% | 4% | 3% | 6% | 2% | 2% | −12% | 1% | 1% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 3% | 12% | −4% | 22% | 25% | 25% | 21% | 22% | 22% | 25% | — | 20% |
| Net profit | ₹122 cr | ₹101 cr | ₹80.0 cr | ₹90.0 cr | ₹96.0 cr | ₹87.0 cr | ₹102 cr | ₹125 cr | ₹134 cr | ₹109 cr | ₹279 cr | ₹143 cr |
| YoY | — | — | — | −4% | −21% | −14% | +27% | +39% | +40% | +25% | +174% | +14% |
| Core profit YoY | — | — | — | +3% | +1% | 0% | +95% | +38% | +37% | +45% | +30% | +13% |
| EPS | ₹9.07 | ₹7.55 | ₹5.22 | ₹6.12 | ₹6.73 | ₹6.15 | ₹6.89 | ₹8.66 | ₹8.82 | ₹7.32 | ₹20.33 | ₹10.28 |
| Flags | · | · | 1 | 1 | 1 | 1 | 1 | ✓ | 1 | 1 | 2 | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Eris Lifesciences Ltd. reported revenue of ₹741 cr (+46.7% on the year) and net profit of ₹96.0 cr (−21.3% on the year) for July to September 2024.
Profit before other income, exceptional items and tax moved +0.8% on the year, against −21.3% for reported profit.
1 check raised a question: Finance cost rose fast and now takes a large bite of operating profit. New borrowing, or a higher rate?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.